If you're launching a dietary supplement containing Osmanthus Extract (Osmanthus fragrans) in the United States, you must prioritize NDI (New Dietary Ingredient) notification first—unless you also plan to market the ingredient as a food additive or in functional foods, in which case GRAS (Generally Recognized As Safe) status should be secured before or concurrently. For most US dietary supplement brands sourcing Osmanthus Extract from China, the ingredient qualifies as a "new dietary ingredient" because it lacks widespread use in the US before October 15, 1994. This means you must file an NDI notification at least 75 days before launching. GRAS is not mandatory for supplements, but having it significantly strengthens your regulatory position and opens doors to food/beverage applications. ---

What Are GRAS and NDI, and How Do They Differ?

Understanding the regulatory pathways is the first step in prioritizing your compliance strategy. GRAS (Generally Recognized As Safe) is a FDA designation for food ingredients that experts generally recognize as safe under the conditions of intended use. GRAS status can be established through:

• Self-affirmed GRAS: Your company's expert panel concludes the ingredient is safe (no FDA review)
• GRAS Notice: You submit a dossier to FDA; FDA issues a "no questions" letter if satisfied

NDI (New Dietary Ingredient) notification is required under the Dietary Supplement Health and Education Act (DSHEA) of 1994. If a dietary ingredient was not marketed in the US before October 15, 1994, you must notify FDA 75 days before introducing it into interstate commerce. Key insight: GRAS covers more applications but is costlier and slower. NDI is faster and cheaper but limited to supplements. ---

Does Osmanthus Extract Require GRAS, NDI, or Both?

This is the critical question for US dietary supplement brands. The short answer: Osmanthus Extract almost certainly requires NDI notification, and GRAS is highly recommended. Why NDI is likely required:

• Osmanthus Extract (from Osmanthus fragrans) is not listed in the FDA's Dietary Supplement Ingredient Directory as a pre-1994 ingredient
• There's no evidence of widespread use in US dietary supplements before October 15, 1994
• The ingredient is relatively new to the US market, primarily imported from China in recent years

When you need GRAS:

• If you plan to use Osmanthus Extract in conventional foods or beverages (e.g., functional teas, health drinks)
• If you want to make structure/function claims that require stronger safety substantiation
• If your marketing strategy emphasizes "FDA-reviewed safety" (GRAS Notice carries more weight than self-affirmed GRAS)

When you might need both:

• If you're a brand like HUM Nutrition or Ritual that sells supplements but also licenses ingredients to food companies
• If you plan to pivot into functional foods later (having GRAS early saves time)

Regulatory gray area: Some brands rely on their supplier's Self-affirmed GRAS and skip NDI notification, arguing that GRAS covers supplement use. This is risky. FDA has stated that GRAS and NDI are separate pathways, and GRAS for food use doesn't automatically satisfy NDI requirements. ---

What's the Recommended Compliance Sequence for US Dietary Supplement Brands?

The answer depends on your business model and timeline.

Scenario 1: Supplement-Only Brand (Most Common)

Priority: NDI first, GRAS later (if expanding)

• File NDI notification immediately (75-day clock starts)
• Use the 75-day waiting period to prepare GRAS dossier (if planning food expansion)
• Launch supplement after NDI acknowledgment
• File GRAS Notice when budget allows (6-12 month timeline)

Scenario 2: Food + Supplement Brand

Priority: GRAS first, then NDI

• File GRAS Notice first (broader market access)
• While GRAS is under review, prepare NDI notification
• File NDI 75 days before supplement launch
• Having GRAS strengthens your NDI submission (safety data can overlap)

Scenario 3: Contract Manufacturing (White Label)

Priority: Check what your CM has already filed

• If your contract manufacturer has already filed NDI for Osmanthus Extract, you may be able to reference it (but consult a regulatory attorney)
• If supplier has GRAS Notice, verify it covers your intended use level
• Never assume supplier's compliance covers your brand

Timeline Comparison

Recommendation: Start with NDI if you're budget-constrained or need to launch quickly. Plan GRAS for 12-18 months later as a market differentiation strategy. ---

What Documentation Do You Need for Each Pathway?

Both GRAS and NDI require substantial documentation, but the focus differs.

GRAS Notice Documentation Checklist

1. Identity information: Botanical name (Osmanthus fragrans), part used (flower), extraction method
2. Safety studies:

- Toxicology studies (acute, subchronic, chronic) - Genotoxicity studies - Reproductive toxicity (if used by pregnant women) - Clinical studies (if available)

1. Historical use evidence: Documentation of safe use in traditional medicine (Chinese herbal medicine references)
2. Manufacturing process: Detailed description, purity specifications, contaminants control
3. Exposure assessment: Estimated daily intake (EDI) based on proposed use level
4. Expert panel report: CVs of experts, consensus statement
5. Labeling: Proposed label statements

Cost driver: Toxicology studies can cost $100,000-$500,000 if not already available.

NDI Notification Documentation Checklist

1. Identity information: Same as GRAS (botanical name, part used, extraction method)
2. History of use: Evidence of traditional use (stronger if pre-1994)
3. Evidence of safety:

- Bibliographic evidence (published studies) - Toxicology data (can reference GRAS studies if available) - Manufacturing quality controls (cGMP compliance)

1. Manufacturing process: Flowchart, quality control points
2. Proposed use level: Serving size, daily intake, duration of use
3. Labeling: Supplement Facts panel, suggested use

Key advantage: NDI can rely more on published literature; GRAS often requires new studies.

Overlapping Documentation: What You Can Reuse

• Botanical identity and authentication
• Manufacturing process description
• Heavy metals/pesticide/residue testing data
• Historical use evidence
• Toxicology studies (if available)

Money-saving tip: If you're filing both, prepare a master dossier that both consultants can use. Don't pay twice for the same literature review. ---

How Much Does Each Pathway Cost, and What's the ROI?

Budget planning is critical for US dietary supplement brands, especially startups.

GRAS Notice Cost Breakdown

NDI Notification Cost Breakdown

Cost of Non-Compliance

• FDA warning letter: $50,000-$200,000 to respond + reputational damage
• Product seizure: Loss of inventory + legal fees
• Import alert: Cannot import ingredient until resolved ($100,000+ in delays)
• Class action lawsuit: $500,000-$5,000,000+ (if adulteration/contamination)

ROI Analysis

Bottom line: NDI is table stakes; GRAS is a competitive advantage. ---

What Are the Common Mistakes When Prioritizing GRAS vs NDI?

Avoid these pitfalls that can delay your launch or trigger FDA enforcement.

Mistake 1: Assuming "Natural" Means GRAS

Many brands believe that because Osmanthus Extract is "natural" and used in traditional Chinese medicine, it's automatically GRAS. False. Natural doesn't equal safe in FDA's eyes. You need scientific evidence.

Mistake 2: Filing NDI Without Checking if GRAS is Needed First

If you file NDI but later realize you need GRAS, you've wasted time. Assess your long-term strategy before filing anything.

Mistake 3: Relying on Supplier's Self-Affirmed GRAS Without FDA Notification

Self-affirmed GRAS has no FDA review. If FDA later disagrees with your supplier's conclusion, your product could be deemed adulterated. For high-risk ingredients like botanical extracts, GRAS Notice (with FDA's "no questions" letter) is safer.

Mistake 4: Not Considering Future Product Line Expansion

If you start with NDI-only and later want to launch a functional beverage, you'll need to go back and file GRAS. This delays expansion by 12-18 months. Think ahead.

Mistake 5: Underestimating Timeline Overlap

Brands often think they can file NDI and GRAS simultaneously. In practice, consultants recommend sequencing them (NDI first, then GRAS) because the safety data preparation overlaps. Doing both at once doubles consultant fees without saving much time. ---

FAQ: GRAS vs NDI for Osmanthus Extract

Q1: Can I sell Osmanthus Extract as a dietary supplement without NDI notification? Technically, if you can prove widespread use before 1994, you might not need NDI. But for Osmanthus Extract, this is nearly impossible. Assume NDI is required. Q2: If my supplier has GRAS, do I still need NDI? Yes, unless the GRAS covers supplement use and you're willing to rely on it solely (risky). NDI and GRAS are separate pathways. Q3: How long does FDA take to respond to GRAS Notice? FDA doesn't have a mandated response time for GRAS Notices. Typically 6-12 months, but can be longer if they have questions. Q4: What happens if I file NDI and FDA issues an objection letter? FDA rarely issues objection letters (they typically just acknowledge receipt). But if they do, you cannot sell the ingredient until you address their concerns. Q5: Can I use Osmanthus Extract in food if I only filed NDI? No. NDI only covers dietary supplements. Food use requires GRAS (or food additive petition, which is even more stringent). Q6: Does GRAS cover all forms of Osmanthus Extract (powder, extract, oil)? Only if the GRAS dossier specifically covers those forms and use levels. A GRAS Notice for Osmanthus Extract powder at 100mg/day doesn't cover osmanthus absolute at 10mg/day. Q7: What's the risk of using Osmanthus Extract without any FDA filing? High. FDA can issue a warning letter, seize your product, or place your ingredient on Import Alert. One enforcement action can bankrupt a small brand. Q8: Should I wait for GRAS/NDI before launching my product? You must wait 75 days after NDI filing (mandatory). For GRAS, you can launch after self-affirmation (riskier) or wait for FDA's "no questions" letter (safer but slower). ---

Conclusion: Your Compliance Priority Checklist

For most US dietary supplement brands sourcing Osmanthus Extract from China, the recommended sequence is:

1. Immediate (Month 0-2): File NDI notification (mandatory for new dietary ingredients)
2. Short-term (Month 2-6): Prepare GRAS dossier while NDI is under review
3. Medium-term (Month 6-18): File GRAS Notice if budget allows
4. Long-term (Month 18+): Leverage GRAS for food/beverage expansion

Final recommendation: Don't cut corners on compliance. The US dietary supplement market is highly regulated, and FDA enforcement is increasing. Brands that invest in proper GRAS and NDI compliance build stronger foundations for long-term growth. ---

Next Steps: Action Plan for Compliance Teams

1. Week 1: Audit your supplier's compliance documentation (GRAS status, NDI history, testing reports)
2. Week 2-4: Engage a regulatory consultant with botanical expertise (recommendations: Nutrasource, EAS Consulting, or SGS)
3. Week 4-8: Prepare NDI notification dossier (literature review, manufacturing docs, safety evidence)
4. Week 8: Submit NDI notification to FDA (75-day clock starts)
5. Month 3-12: Simultaneously prepare GRAS dossier (if budget allows)
6. Month 6: Launch supplement (after NDI 75-day wait period)
7. Month 12-18: Submit GRAS Notice (if pursuing food/beverage expansion)

Budget allocation:

• NDI preparation: $15,000-$30,000
• GRAS preparation: $50,000-$150,000 (if studies exist)
• Annual compliance maintenance: $5,000-$10,000

Risk mitigation: Maintain a compliance reserve fund (10-15% of annual revenue) to handle potential FDA inquiries or label claim disputes.

This article was published on June 27, 2026, and last updated on June 27, 2026. The article will be continuously updated.